Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling
- 1k Downloads
It has been suggested that combined effect of natural products may improve the treatment effectiveness in combating proliferation of cancer cells. Here, we examined the combined anticancer activities of compounds of three natural origin including baicalein, curcumin, and resveratrol with chemotherapy drug paclitaxel respectively, which showed that combination of paclitaxel with curcumin exhibited synergistic growth inhibition and induced significant apoptosis in MCF-7 cell lines. Treatment of MCF-7 cell lines with paclitaxel and curcumin induced the apoptosis of regulatory protein Bcl-2 but decreased Bax expression. In addition, simultaneous treatment with paclitaxel and curcumin strongly inhibited paclitaxel-induced activities of EGFR signaling. Furthermore, the combination of paclitaxel and curcumin exerted increased anti-tumor efficacy on mouse models. Overall, our data described the promising therapeutic potential and underlying mechanisms of combining paclitaxel with curcumin in treating breast cancer.
KeywordsBreast cancer Paclitaxel Natural products Synergism Apoptosis EGFR signaling
This work was supported by National Natural Science Foundation of China (Grant Nos. 81302800 and 81102414), the National Science Foundation for Post-doctoral Scientists of China (Grant No. 2013M532062).
Conflict of interest
- Chao, J.I., W.C. Su, and H.F. Liu. 2007. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Molecular Cancer Therapeutics 6: 3039–3048.PubMedCrossRefGoogle Scholar
- Clark, C.A., M.D. Mceachern, S.H. Shah, Y. Rong, X. Rong, C.L. Smelley, G.C. Caldito, F.W. Abreo, and C.O. Nathan. 2010. Curcumin inhibits carcinogen and nicotine-induced mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer Prevention Research 3: 1586–1595.PubMedCrossRefGoogle Scholar
- Maier-Lenz, H., B. Hauns, B. Haering, J. Koetting, K. Mross, C. Unger, T. Bauknecht, A. du Bois, H.G. Meerpohl, N. Hollaender, and K. Diergarten. 1997. Phase I study of paclitaxel administered as a 1-hour infusion: Toxicity and pharmacokinetics. Seminars in Oncology 24(Suppl. 19): 16–19.Google Scholar
- Sharma, R.A., S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, H.R. Hewitt, T.H. Marczylo, B. Morgan, D. Hemingway, S.M. Plummer, M. Pirmohamed, A.J. Gescher, and W.P. Steward. 2004. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clinical Cancer Research 10: 6847–6854.PubMedCrossRefGoogle Scholar
- Takahashi, H., M.C. Chen, H. Pham, E. Angst, J.C. King, J. Park, E.Y. Brovman, H. Ishiguro, D.M. Harris, H.A. Reber, O.J. Hines, A.S. Gukovskaya, V.L. Go, and G. Eibl. 2011. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochimica et Biophysica Acta 1813: 1465–1474.PubMedCentralPubMedCrossRefGoogle Scholar